Australia markets close in 5 hours 19 minutes

Bionomics Limited (BNO.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0470+0.0010 (+2.17%)
As of 10:24AM AEST. Market open.
Full screen
Previous close0.0460
Open0.0450
Bid0.0460 x 2640300
Ask0.0480 x 16362900
Day's range0.0450 - 0.0470
52-week range0.0440 - 0.2050
Volume378,937
Avg. volume586,042
Market cap63.607M
Beta (5Y monthly)2.74
PE ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings date23 Aug 2022 - 29 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

    ADELAIDE, Australia, June 27, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a fireside chat at the First Annual H.C. Wainwright

  • GlobeNewswire

    Bionomics Investor Webinar

    ADELAIDE, Australia, June 13, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO |Nasdaq: BNOX ), (Bionomics or the Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, invites shareholders and interested parties to attend an investor webinar with Executive Chairman Dr. Errol De Souza and Vice President of St

  • GlobeNewswire

    Bionomics Limited to Participate in Upcoming Investor Conferences

    ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences: Citibank Biotech’